Key statistics dashboard for Lunai Bioworks Inc. (LNAI). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
Stock Data
| Price | $2.17 |
| Market Cap | $10M |
| Beta | 0.49 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.04 |
| Price / Book | -0.72 |
| P/S | 474.13 |
| P/FCF | -1.89 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -360.71% |
| EBIT Margin | -609673.10% |
| EBITDA Margin | -609212.40% |
| Operating Margin | -46991.97% |
| Net Margin | -612568.11% |
Financial Health
| Current Ratio | 0.19 |
| Quick Ratio | 0.19 |
| Cash Ratio | 0.16 |
| Debt / Equity | -0.15 |
| Debt / Assets | 14.31% |
| Interest Coverage | -16.23 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -97.60 |
Per-Share Data
| Revenue per share | 0.01 |
| Book Value per share | -3.06 |
| Cash per share | 1.01 |
| FCF per share | -1.68 |
| Tangible Book Value per share | -5.00 |
| Dividend per share | 0.00 |
Explore sector: Healthcare · Biotechnology
More sections of LNAI: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks